Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Thyrointegrin αvβ3 antagonist with potent Affinity in the treatment of Glioblastoma

ABSTRACT: Thyrointegrin αvβ3 antagonist with potent Affinity in the treatment of Glioblastoma

PROVIDER: PRJNA761989 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Novel Thyrointegrin αvβ3 antagonist (fp-PMT) with potent affinity in the treatment of cancer

Project description:Novel Thyrointegrin αvβ3 antagonist (fp-PMT) with potent affinity in the treatment of cancer

| PRJNA761985 | ENA

Novel Thyrointegrin αvβ3 antagonist (fp-PMT) with potent affinity in the treatment of cancer

Project description:Microarray analysis was carried out on Glioblastoma (GBM 10181360, GBM 021913 and U87 cells), Bladder cancer (JBV253), skin cancer (A375) and Acute Myelod Leukemia (AML) (KG1A and K562 cells) exposed to fb-PMT at 30 µM concentration. Our genome-wide microarray screens demonstrated that fb-PMT appears to exert its potent anticancer actions on human cancer cells through the molecular interference mechanism with multiple signaling pathways supporting growth and survival of leukemic cells. Notably, fb-PMT had a significant effect on different molecular pathways that contribute to the anticancer activity such as cell cycle control (MYC), survival and maintenance of stem cells (HIF1A; TFAP2C), essential features of the malignant phenotype (TWIST1; SNAI). Furthermore, the fb-PMT-induced significant transcriptional pathway’s activation includes RB1; IRF9; MAML1; RAP1A; and GATA4 pathways, which known to play an important role in anticancer activity. Finally, Consistent with our previous reports on the crosstalk between integrin αvβ3 and ERα which contributes to the induced proliferation of cancer cells, we found that fb-PMT interference with estrogen signaling. The αvβ3 agonist (thyroid hormone) was associated with increased phosphorylation and nuclear enrichment of estrogen receptor α (ERα).

2021-09-11 | GSE183772 | GEO

Thyrointegrin αvβ3 antagonist with potent Affinity in the treatment of Glioblastoma

Project description:Microarray analysis was carried out on Glioblastoma GBM 10181360 and U87 cells treated with PBS for 24 h and 48 h .

2021-09-11 | GSE183773 | GEO

POSTN secreted from glioblastoma stem cells can recruit microglia and upregulate CD70 expression in microglia through the αVβ3/PI3K/AKT/NFκB pathway [HMC3_ChIP-seq]

Project description:Glioblastoma (GBM), classified as a grade 4 glioma, is the most prevalent intrinsic malignancy of the central nervous system. Glioblastoma stem cells (GSCs) are small populations of GBM cells with self-renewal and multilineage differentiation capabilities and are considered responsible for the tumorigenesis and development of GBM. POSTN secreted from glioblastoma stem cells can recruit microglia and upregulate CD70 expression in microglia through the αVβ3/PI3K/AKT/NFκB pathway, which in turn promotes Treg development and functionality and supports the formation of an immunosuppressive tumor microenvironment.

2024-08-01 | GSE273251 | GEO

Transcription profiling of human primary osteoblasts treated with estradiol or the pure antagonist ICI 182,780a potent inhibitor of estrogen receptor signaling

Project description:Transcriptional profiling of estrogen regulated genes in human primary osteoblasts. The cells were either treated with estradiol (1 nM) or the pure antagonist ICI 182,780 (Faslodex), which acts as a potent inhibitor of estrogen receptor signaling.

2007-08-01 | E-MEXP-1053 | biostudies-arrayexpress

Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression

Project description:Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression

| PRJNA544318 | ENA

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Project description:Glioblastoma, the most aggressive primary brain cancer, has dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we here systematically screen repurposable neuroactive drugs in glioblastoma patient surgery material using a clinically concordant and single-cell resolved platform. Profiling >2,500 ex vivo drug responses across 27 patients and 132 drugs identified class-diverse neuroactive drugs with potent anti-glioblastoma efficacy that were validated across model systems. Interpretable molecular machine learning of drug-target networks revealed neuroactive convergence on AP-1/BTG-driven glioblastoma suppression, enabling expanded in silico screening of >1 million compounds with high patient validation accuracy. Deep multi-modal profiling confirmed Ca2+-driven AP-1/BTG-pathway induction as a neuro-oncological glioblastoma vulnerability, epitomized by the antidepressant Vortioxetine synergizing with current standard-of-care chemotherapies in vivo. These findings establish an actionable framework for glioblastoma treatment rooted in its neural etiology.

| MSV000090357 | MassIVE

Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells

Project description:We have found that thyroid hormones (THs), acting as soluble integrin αvβ3 ligands, activate growth-related signaling pathways in T-cell lymphomas (TCL). Specifically, TH-activated αvβ3 integrin signaling promotes TCL proliferation and angiogenesis, in part, via the up-regulation of VEGF. CUTLL1 cells were treated with T3- and T4-bound agarose or agarose alone for 24hrs. Total RNA was harvested from cells and used for expression profiling via RNA-seq.

2015-02-18 | E-GEOD-63122 | biostudies-arrayexpress

Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells

2015-02-18 | GSE63122 | GEO

AhR antagonist

Project description:AhR antagonist

| PRJNA766233 | ENA